Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Influence of patient age on biochemical freedom from disease in patients undergoing conformal proton radiotherapy of organ-confined prostate cancer.

Rossi CJ Jr, Slater JD, Yonemoto LT, Jabola BR, Bush DA, Levy RP, Grove R, Slater JM.

Urology. 2004 Oct;64(4):729-32.

PMID:
15491710
2.

Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancer.

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Adamovich E.

Urology. 2004 Oct;64(4):754-9.

PMID:
15491715
3.

Influence of body mass index on biochemical outcome after permanent prostate brachytherapy.

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen Z, Lief JH, Adamovich E.

Urology. 2005 Jan;65(1):95-100.

PMID:
15667872
4.

Does age matter in the selection of treatment for men with early-stage prostate cancer?

Konski A, Eisenberg D, Horwitz E, Hanlon A, Pollack A, Hanks G.

Cancer. 2006 Jun 15;106(12):2598-602.

5.

Long-term outcomes in younger men following permanent prostate brachytherapy.

Shapiro EY, Rais-Bahrami S, Morgenstern C, Napolitano B, Richstone L, Potters L.

J Urol. 2009 Apr;181(4):1665-71; discussion 1671. doi: 10.1016/j.juro.2008.11.122. Epub 2009 Feb 23.

PMID:
19233394
6.

Long-term results in three-dimensional conformal radiotherapy of localized prostate cancer at moderate dose (66 Gy).

Goldner G, Wachter S, Wachter-Gerstner N, Dieckmann K, Pötter R.

Strahlenther Onkol. 2006 Sep;182(9):537-42.

PMID:
16944376
7.

Prostate cancer disease-free survival after radical retropubic prostatectomy in patients older than 70 years compared to younger cohorts.

Malaeb BS, Rashid HH, Lotan Y, Khoddami SM, Shariat SF, Sagalowsky AI, McConnell JD, Roehrborn CG, Koeneman KS.

Urol Oncol. 2007 Jul-Aug;25(4):291-7.

PMID:
17628294
8.

Influence of age on the pattern and outcome of external beam radiotherapy for clinically localized prostate cancer.

Ogawa K, Nakamura K, Onishi H, Koizumi M, Sasaki T, Araya M, Miyabe Y, Otani Y, Teshima T; Japanese Patterns of Care Study Working Subgroup of Prostate Cancer.

Anticancer Res. 2006 Mar-Apr;26(2B):1319-25.

9.

3D conformal radiation therapy for prostate cancer in elderly patients.

Geinitz H, Zimmermann FB, Thamm R, Schumertl A, Busch R, Molls M.

Radiother Oncol. 2005 Jul;76(1):27-34.

PMID:
15990188
10.
12.

What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?

Feigenberg SJ, Hanlon AL, Horwitz EM, Uzzo RG, Eisenberg DF, Pollack A.

Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1003-10.

PMID:
15752879
13.

Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.

Kupelian P, Kuban D, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A.

Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):415-9.

PMID:
15667961
14.

Biochemical and functional outcomes following brachytherapy with or without supplemental therapies in men < or = 50 years of age with clinically organ-confined prostate cancer.

Merrick GS, Wallner KE, Galbreath RW, Butler WM, Brammer SG, Allen ZA, Lief JH, Adamovich E.

Am J Clin Oncol. 2008 Dec;31(6):539-44. doi: 10.1097/COC.0b013e318172dcb7.

PMID:
19060584
15.
16.

The impact of primary Gleason grade on biochemical outcome following brachytherapy for hormone-naive Gleason score 7 prostate cancer.

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen ZA, Adamovich E.

Cancer J. 2005 May-Jun;11(3):234-40.

PMID:
16053667
17.

Hypofractionated radiotherapy with carbon ion beams for prostate cancer.

Tsuji H, Yanagi T, Ishikawa H, Kamada T, Mizoe JE, Kanai T, Morita S, Tsujii H; Working Group for Genitourinary Tumors.

Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1153-60. Epub 2005 Jun 28.

PMID:
15990247
18.

Whole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma.

Aizer AA, Yu JB, McKeon AM, Decker RH, Colberg JW, Peschel RE.

Int J Radiat Oncol Biol Phys. 2009 Dec 1;75(5):1344-9. doi: 10.1016/j.ijrobp.2008.12.082. Epub 2009 May 21.

PMID:
19464821
19.
20.

Monotherapeutic brachytherapy for clinically organ-confined prostate cancer.

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Adamovich E.

W V Med J. 2005 Jul-Aug;101(4):168-71.

PMID:
16296198

Supplemental Content

Support Center